A case/non-case study of a national pharmacovigilance database to explore drug-induced acute kidney injury

• Type: Article in International Scientific Journal
• Date: 2025

Authors

Oliveira, CL (Author) Other; Fernandez-Llimos, F (Author) FFUP; da Costa, FA (Author) Other; Aguiar, JP (Author) Other; Duarte-Ramos, F (Author) Other

Journal

Title: International Journal of Clinical Pharmacy

ISSN: 2210-7703

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-018-X65

DOI: 10.1007/s11096-025-01940-0

Abstract (EN): BackgroundMonitoring safety throughout a medicine's lifecycle is essential. Pharmacovigilance systems are rich sources contributing to this aim in a real world context.AimTo identify and estimate disproportionality rates associated with the drugs that are most frequently reported to induce acute kidney injury (AKI).MethodA case/non-case study was conducted, using data extracted in 2022 from the Portuguese National Pharmacovigilance Database for the period between 01/01/2009 and 12/31/2020. Cases were identified using the 'Acute Renal Failure' standardized MedDRA query, all remaining reports were considered non-cases, and a random sample without replacement of 4 non-cases per case was extracted. Data were expressed as the reporting odds ratio (ROR) and the 95% confidence interval.ResultsDuring this 11-year period, 352 AKI cases were identified, representing 0.7% of the 53,505 reports received. A total of 559 different drugs were considered 'suspect' in these AKI cases. Three therapeutic subgroups (ATC2) showed a significant ROR: antithrombotic agents (ROR 6.72; 95% CI 2.23-20.22), antivirals for systemic use (ROR 4.02; 95% CI 2.76-5.87), and antineoplastic drugs (ROR 2.14; 95% CI 1.48-3.11). Additionally, we identified individual drugs with significant RORs where no class effect was observed, namely mycophenolic acid, ciclosporin, tacrolimus, simvastatin, prednisolone, vancomycin, and deferasirox. In total, eleven drugs were identified as potentially associated with the occurrence of AKI.ConclusionThis study highlights the importance of clinical pharmacy activities in closely monitoring renal function of people with known risk factors or those prescribed medications known to increase the risk of AKI. Some of the medications identified require further investigation to validate their association with AKI.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9